The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

( NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea ...

Sleep apnea causes people to stop and start breathing repeatedly Zepbound is first drug approved by FDA to help treat it Two studies found that those who used it saw reduction in apnea events ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans ...

The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release.

Clinical research by Zepbound's manufacturer Eli Lilley found that the drug's active ingredient tirzepatide reduces sleep apnea by about 60%.

The weight loss drug Zepbound has become the first prescription medication approved to treat obstructive sleep apnea. The Food and Drug Administration on Friday authorized the use of Zepbound ...

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound.The medicine, part of the class known as GLP-1 ...